Clinical Efficacy Of Postoperative Intravenous Chemotherapy Combined With Hyperthermic Intraperitoneal Therapy After Advanced Ovarian Cancer Cytoreductive Surgery

Objective : To investigate the clinical efficacy and side effects of intravenous chemotherapy combined with intraperitoneal hyperthermic perfusion therapy in patients with advanced ovarian cancer after cytoreductive surgery,and provide reference for future clinical treatment.Methods:Retrospective analysis in January 2015 to October 2017 in the second hospital of hebei medical university,29 cases of patients with adanced oarian cancer,including 14 cases of observation group(CRS + docetaxel,oxaliplatin iv chemotherapy + hyperthermic intraperitoneal chemotherapy)and control group in 15 cases(CRS + docetaxel,oxaliplatin iv chemotherapy+ hyperthermic intraperitoneal perfusion),compare the clinical efficacy of two groups of treatment,ascites control,adverse reaction,recurrence and survival,and so on and so forth.Results:The observation group and the control group had no statistical significance in tumor control,CA125 level of PFS,OS,3 cycles of chemotherapy in difference(P>0.05);two groups of ascites control comparison,observation group than the control group,there was significant difference(P<0.05);adverse reaction in the observation group the gastrointestinal symptoms slightly higher,the difference was statistically significant(P < 0.05);there were no differences in the other adverse reactions(P > 0.05).Conclusions:Compared with hyperthermic intraperitoneal perfusion,hyperthermic intraperitoneal chemotherapy can reduce the status of ascites in advanced ovarian cancer and improve the quality of life of the patients.It is worthy of clinical application.